Trending
Know your HIV status- Ogun govt, UNESCO to NYSC members is trending now Abia to Recruit More Health Workers, Plans 35th Anniversary is trending now OneHealth by AXA expands access to specialist, preventive care through Victoria Island Me… is trending now Lassa fever death toll in Nigeria rises to 237 is trending now Cellulose Quantum Dots Boost Hydrogen Photocatalysis is trending now Machine learning predicts forest soil fungal diversity from drone images is trending now Italian scientists develop solar corona observation device is trending now Europe prepares for historic total solar eclipse as Nigeria awaits 2027 "ring of fire" is trending now 'I hope he comes back' - Barcelona star Fermin Lopez breaks silence on Ronald Araujo's sh… is trending now Nigeria 'still have hope' for 2027 World Cup spot is trending now €50m offer REJECTED! Barcelona knock back PSG's opening Ferran Torres bid as Spanish forw… is trending now Carabao Cup draw: Chelsea to host Luton, Tottenham play Charlton in second round is trending now Know your HIV status- Ogun govt, UNESCO to NYSC members is trending now Abia to Recruit More Health Workers, Plans 35th Anniversary is trending now OneHealth by AXA expands access to specialist, preventive care through Victoria Island Me… is trending now Lassa fever death toll in Nigeria rises to 237 is trending now Cellulose Quantum Dots Boost Hydrogen Photocatalysis is trending now Machine learning predicts forest soil fungal diversity from drone images is trending now Italian scientists develop solar corona observation device is trending now Europe prepares for historic total solar eclipse as Nigeria awaits 2027 "ring of fire" is trending now 'I hope he comes back' - Barcelona star Fermin Lopez breaks silence on Ronald Araujo's sh… is trending now Nigeria 'still have hope' for 2027 World Cup spot is trending now €50m offer REJECTED! Barcelona knock back PSG's opening Ferran Torres bid as Spanish forw… is trending now Carabao Cup draw: Chelsea to host Luton, Tottenham play Charlton in second round is trending now
Accenture

What Makes Stevanato Group S.p.A. (STVN) a Worthy Stock?

What Makes Stevanato Group S.p.A. (STVN) a Worthy Stock?

TimesSquare Capital Management, an equity investment management company, released its “U.S. SMID Cap Growth Strategy” third-quarter investor letter.  The same can be downloaded here. In the third quarter, the U.S. SMID Cap Growth Composite fell -2.65% (gross) and -2.89%...

TimesSquare Capital Management, an equity investment management company, released its “U.S. SMID Cap Growth Strategy” third-quarter investor letter.  The same can be downloaded here. In the third quarter, the U.S. SMID Cap Growth Composite fell -2.65% (gross) and -2.89% (net) compared to the Russell 2500 Growth Index’s -6.84% decline.  This quarter, the small-to-mid-cap growth stocks that performed better had lower betas or higher returns on equity. Stocks that lacked short-term earnings or had exorbitant valuations (as measured by price/earnings) were penalized. In the third quarter, the portfolio beat the Russell 2500 Growth Index in this setting. In addition, please check the fund’s top five holdings to know its best picks in 2023.

TimesSquare Capital U.S. SMID Cap Growth Strategy highlighted stocks like Stevanato Group S.p.A. (NYSE:STVN) in the third quarter 2023 investor letter. Headquartered in Piombino Dese, Italy, Stevanato Group S.p.A. (NYSE:STVN) produces and distributes products and processes for biopharma and healthcare. On December 26, 2023, Stevanato Group S.p.A. (NYSE:STVN) stock closed at $27.26 per share. One-month return of Stevanato Group S.p.A. (NYSE:STVN) was 4.81%, and its shares gained 55.33% of their value over the last 52 weeks. Stevanato Group S.p.A. (NYSE:STVN) has a market capitalization of $7.237 billion.

TimesSquare Capital U.S. SMID Cap Growth Strategy made the following comment about Stevanato Group S.p.A. (NYSE:STVN) in its Q3 2023 investor letter:

“New to the strategy was Stevanato Group S.p.A. (NYSE:STVN), which manufactures glass packaging for syringes, autoinjectors, and other pharmaceutical needs. The company should benefit from the commercial growth of weight loss and diabetes drugs, which are expected to be blockbusters and use this type of drug delivery system.”

A scientist in a laboratory observing a drug delivery system through a microscope.

Stevanato Group S.p.A. (NYSE:STVN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 11 hedge fund portfolios held Stevanato Group S.p.A. (NYSE:STVN) at the end of third quarter which was 10 in the previous quarter.

We discussed Stevanato Group S.p.A. (NYSE:STVN) in another article and shared Artisan Small Cap Fund’s views on the company. In addition, please check out our hedge fund investor letters Q3 2023 page for more investor letters from hedge funds and other leading investors.

 

Suggested Articles:

20 US Cities with the Lowest Rental Vacancy Rates 25 Best Online Engineering Degree Programs Heading Into 2024 15 Best Long Term Care Insurance Companies Heading into 2024

Disclosure: None. This article is originally published at Insider Monkey.

View original source →

Related

More from Insider Monkey - Free Hedge Fund and Insider Trading Data